NAVCO Pharmaceuticals Inc. (TSXV:NAV)

Canada · Delayed Price · Currency is CAD

0.0050

0.00 (0.00%)

Aug 18, 2026, 2:19 PM EST

NAVCO Pharmaceuticals Financials Overview

Financials in millions CAD. Fiscal year is October - September.

Millions CAD. Fiscal year is Oct - Sep.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Revenue	-	-	-	-	0.06	0.02
Revenue Growth	-	-	-	-	278.32%	-
Gross Profit	-	-	-	-	0.06	0.02
Operating Income	-0.04	-0.05	-1.57	-1.44	-0.45	-0.51
Net Income	-0.07	-0.08	-1.72	-2.15	-0.47	-0.53
Earnings Per Share	-0.00	-0.00	-0.03	-0.07	-0.02	-0.04
EPS Growth	-	-	-	-	-	-

Cash & Debt

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Cash & Investments	0	0	0.01	0.23	0	0
Total Debt	0.11	0.09	0.1	0.11	0.9	0.29
Net Cash (Debt)	-0.1	-0.08	-0.09	0.12	-0.9	-0.29
Net Cash Growth	-	-	-	-	-	-
Net Cash Per Share	-0.00	-0.00	-0.00	0.00	-0.04	-0.02

Cash Flow & CapEx

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Operating Cash Flow	-0.04	-0.02	-0.25	-1.78	-0	-0.24
Capital Expenditures	-	-	-	-	-	-0.07
Free Cash Flow	-0.04	-0.02	-0.25	-1.78	-0	-0.31
Free Cash Flow Growth	-	-	-	-	-	-

Margins

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Gross Margin	-	-	-	-	100.00%	100.00%
Operating Margin	-	-	-	-	-766.48%	-3309.64%
Pretax Margin	-	-	-	-	-791.92%	-3389.75%
Profit Margin	-	-	-	-	-791.92%	-3389.75%
FCF Margin	-	-	-	-	-7.72%	-2027.27%

Valuation

Selected indicators aren't available for this stock.